Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for patients (pts) with castration-resistant prostate cancer (CRPC).

被引：0
|
作者：
Medioni, J.
Ferrero, J.
Deplanque, G.
Maurina, T.
Rodier, J. P.
Raymond, E.
Allyon, J.
Renaux, S.
Dufour-Lamartinie, J.
Oudard, S.
机构：
[1] Georges Pompidou European Hosp, Paris, France
[2] Ctr Antoine Lacassagne, F-06054 Nice, France
[3] Grp Hosp St Joseph, Paris, France
[4] Jean Minjoz Hosp, Besancon, France
[5] Hop Xavier Bichat, Paris, France
[6] Beaujon Univ Hosp, Clichy, France
[7] Hybrigenics, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4605
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4605
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for castration-resistant prostate cancer (CRPC) patients (pts)
    Medioni, J.
    Deplanque, G.
    Ferrero, J.
    Maurina, T.
    Rodier, J. P.
    Raymond, E.
    Allyon, J.
    Renaux, S.
    Dufour-Lamartinie, J.
    Oudard, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [2] DOSE FINDING AND EFFICACY PHASE 2 STUDY OF INECALCITOL, A NEW VDR AGONIST, IN COMBINATION WITH DOCETAXEL-PREDNISONE REGIMEN FOR CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS (PTS)
    Medioni, Jacques
    Deplanque, Gael
    Maurina, Tristan
    Ferrero, Jean-Marc
    Rodier, Jean-Michel
    Raymond, Eric
    Ayllon, Jorge
    Renaux, Stephanie
    Dufour-Lamartinie, Jean-Francois
    Oudard, Stephane
    JOURNAL OF UROLOGY, 2011, 185 (04): : E285 - E286
  • [3] Dose finding of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for castrate-resistant prostate cancer (HRPC) patients (pts)
    Medioni, J.
    Deplanque, G.
    Ferrero, J. M.
    Maurina, T.
    Rodier, J. M.
    Raymond, E.
    Allyon, G.
    Renaux, S.
    Dufour-Lamartinie, J. F.
    Oudard, S.
    EJC SUPPLEMENTS, 2010, 8 (07): : 136 - 136
  • [4] Dose finding and safety analysis of inecalcitol in combination with docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients (pts)
    Medioni, J.
    Deplanque, G.
    Maurina, T.
    Ferrero, J. M.
    Rodier, J. M.
    Raymond, E.
    Allyon, J.
    Kalla, S.
    Dufour-Lamartinie, J. F.
    Oudard, S.
    EJC SUPPLEMENTS, 2009, 7 (02): : 415 - 415
  • [5] Dose finding and safety analysis of inecalcitol in combination with a docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients
    Medioni, J.
    Deplanque, G.
    Maurina, T.
    Ferrero, J. M.
    Rodier, J. M.
    Raymond, E.
    Allyon, J.
    Kalla, S.
    Dufour-Lamartinie, J. F.
    Oudard, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients
    Medioni, Jacques
    Deplanque, Gael
    Ferrero, Jean-Marc
    Maurina, Tristan
    Rodier, Jean-Michel P.
    Raymond, Eric
    Allyon, Jorge
    Maruani, Gerard
    Houillier, Pascal
    Mackenzie, Sarah
    Renaux, Stephanie
    Dufour-Lamartinie, Jean-Francois
    Elaidi, Reza
    Lerest, Celine
    Oudard, Stephane
    CLINICAL CANCER RESEARCH, 2014, 20 (17) : 4471 - 4477
  • [7] The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study
    Mahammedi, Hakim
    Planchat, Eloise
    Pouget, Melanie
    Durando, Xavier
    Cure, Herve
    Guy, Laurent
    Van-Praagh, Isabelle
    Savareux, Laurent
    Atger, Marc
    Bayet-Robert, Mathilde
    Gadea, Emilie
    Abrial, Catherine
    Thivat, Emilie
    Chollet, Philippe
    Eymard, Jean-Christophe
    ONCOLOGY, 2016, 90 (02) : 69 - 78
  • [8] Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first-line treatment in castration resistant prostate cancer (CRPC) patients (Pts)
    Fontana, A.
    Bocci, G.
    Galli, L.
    Derosa, L.
    Minuti, G.
    D'Arcangelo, M.
    Santini, D.
    Landi, L.
    Bursi, S.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Docetaxel and curcuminoids (CCM) combination in patients with castration-resistant prostate cancer (CRPC): A phase II study.
    Mahammedi, Hakim
    Pouget, Melanie
    Planchat, Eloise
    Cure, Herve
    Durando, Xavier
    Bayet-Robert, Mathilde
    Van-Praagh, Isabelle
    Atger, Marc
    Guy, Laurent
    Abrial, Catherine
    Chollet, Philippe J. M.
    Eymard, Jean-Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC)
    Rathkopf, D. E.
    Chi, K. N.
    Vaishampayan, U.
    Hotte, S.
    Vogelzang, N.
    Alumkal, J.
    Agrawal, M.
    Nydam, T. M.
    Fandi, A.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345